AKR1B1
Aldo-keto reductase family 1 member B1
As of the edition of 20 October 2026, AKR1B1 (aldo-keto reductase family 1 member B1, UniProt P15121) has 7 drugs tested at it and 6 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15121
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 177
- Disease areas
- Nutrition and metabolism; Nervous system; Hormones; Inherited and neonatal; Heart and blood vessels; Cancer; Digestive system; Eye
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 3 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Caficrestat | Active | Phase 3 | none listed |
| Epalrestat | Stopped | Phase 4 | none listed |
| Govorestat | Status not established | Phase 3 | none listed |
| Ranirestat | Went quiet | Phase 3 | none listed |
| Lidorestat | Went quiet | Phase 2 | none listed |
| Sorbinil | Went quiet | Phase 3 | none listed |
| Tolrestat | Withdrawn from market | No phase stated | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Eisai | Route A |
| The Institute for Diabetes Discovery | Route A |
| Sumitomo Pharma | Route A |
The other 3 companies at AKR1B1
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at AKR1B1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.